title: Inhibition of telomerase activity by a distamycin derivative: effects on cell proliferation and induction of apoptosis in human cancer cells.
abstract: In this study, we evaluated the potential of the distamycin derivative MEN 10716 as a telomerase inhibitor. Exposure of human melanoma cell extracts to MEN 10716 induced a dose-dependent inhibition of telomerase activity, with an IC50 of 24+/-3 microM. When intact JR8 melanoma cells were chronically exposed to the drug (200 microM every other day for 50 days), a marked inhibition (>80%) of the enzyme's catalytic activity was consistently observed starting from day 1. At later points in time, MEN 10716 inhibited melanoma cell proliferation and induced apoptosis. Cells surviving MEN 10716 exposure were characterised by a higher melanin content and a greater expression of p16(INK4A) protein than control cells. The effects of MEN 10716 were subsequently evaluated in different tumour cell systems. In particular, even in the H460 non-small cell lung cancer cell line, chronic exposure of the cells to the drug (100 microM every other day for 50 days) induced a consistent inhibition (>85%) of telomerase activity, a reduction of cell proliferation potential, and apoptosis. Conversely, MEN 10716 treatment did not appreciably inhibit cell proliferation in the U2-OS telomerase-negative human osteogenic sarcoma cell line. Interestingly, no variation in the mean telomere length was observed in MEN 10716-treated JR8 melanoma cells, whereas an appreciable increase in the mean telomere length was found in H460 lung cancer cells after drug exposure. Overall, the results of the study indicate that MEN 10716 is a possible telomerase inhibitor and suggest that abrogation of telomerase activity can affect cell proliferation even through pathways that are not dependent on telomere erosion.
authors.affiliation: Dipartimento di Oncologia Sperimentale, Unità Operativa #10, Istituto Nazionale Tumori, Milan, Italy. zaffaroni@istitutotumori.mi.it
authors.forename: N
authors.initials: N
authors.lastname: Zaffaroni
authors.forename: S
authors.initials: S
authors.lastname: Lualdi
authors.forename: R
authors.initials: R
authors.lastname: Villa
authors.forename: D
authors.initials: D
authors.lastname: Bellarosa
authors.forename: C
authors.initials: C
authors.lastname: Cermele
authors.forename: P
authors.initials: P
authors.lastname: Felicetti
authors.forename: C
authors.initials: C
authors.lastname: Rossi
authors.forename: L
authors.initials: L
authors.lastname: Orlandi
authors.forename: M G
authors.initials: MG
authors.lastname: Daidone
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000998:Antiviral Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy / Q000201:enzymology; D002455:Cell Division / Q000187:drug effects; D004214:Distamycins / Q000494:pharmacology* / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy / Q000201:enzymology; D008545:Melanoma / Q000188:drug therapy / Q000201:enzymology; D012516:Osteosarcoma / Q000188:drug therapy / Q000201:enzymology; D019098:Telomerase / Q000037:antagonists & inhibitors*; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D000998:Antiviral Agents; D004214:Distamycins; C467646:MEN 10716; C030000:stallimycin; D019098:Telomerase